OCM
VRTX icon

Osterweis Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Osterweis Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.38K Hold
21
– – ﹤0.01% 229
2025
Q4 		$9.52K Hold
21
– – ﹤0.01% 284
2025
Q3 		$8.22K Hold
21
– – ﹤0.01% 267
2025
Q2 		$9.35K Buy
+21
New +$9.68K ﹤0.01% 275
2022
Q4 		– Sell
-6
Closed -$2K – 261
2022
Q3 		$2K Buy
+6
New +$1.73K ﹤0.01% 233

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Osterweis Capital Management's VRTX Position: Q1 2026 in Review

Osterweis Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 21 shares worth $9.38K. The position accounts for ﹤0.01% of the portfolio, ranked #229.

Osterweis Capital Management first reported a position in VRTX in Q3 2022 and has held it in 5 quarters since. The position peaked at $9.52K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Osterweis Capital Management held 21 shares of Vertex Pharmaceuticals worth $9.38K as of Q1 2026.
  • Osterweis Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Osterweis Capital Management's portfolio in Q1 2026, its #229 holding.
  • Osterweis Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
  • Osterweis Capital Management's Vertex Pharmaceuticals position peaked at $9.52K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Osterweis Capital Management's 13F filing for Q1 2026, filed 15 May 2026.